SRPT

SRPT

USD

Sarepta Therapeutics Inc. Common Stock (DE)

$16.200+0.890 (5.813%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$15.310

高値

$17.750

安値

$15.080

出来高

2.09M

企業ファンダメンタルズ

時価総額

1.7B

業種

バイオテクノロジー

United States

取引統計

平均出来高

7.10M

取引所

NMS

通貨

USD

52週レンジ

安値 $10.42現在値 $16.200高値 $138.81

関連ニュース

Analyst Upgrades

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid Elevidys sales weakness.

もっと見る
Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance
Analyst Upgrades

Baird Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $15

Baird analyst Brian Skorney maintains Sarepta Therapeutics with a Neutral and lowers the price target from $21 to $15.

もっと見る
Baird Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $15
Reuters

Futures tumble after Wall St banks warn of market pullback, Palantir slides

U.S. stock futures tumbled on Tuesday as investors questioned lofty valuations in the technology sector after top Wall Street banks warned of a stock market selloff and AI darling Palantir's sales forecast failed to lift the mood.

もっと見る
Futures tumble after Wall St banks warn of market pullback, Palantir slides
Reuters

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting disease missed a key goal, deepening concerns about the company's treatment pipeline.

もっと見る
Sarepta slumps as gene therapy setback adds to drug pipeline woes
BusinessWire

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Sarepta announces completion of the confirmatory trial commitment for its ultra-rare disease PMO therapies AMONDYS 45 and VYONDYS 53: While the ESSENCE study did not achieve statistical significance on its primary

もっと見る
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
Analyst Upgrades

Piper Sandler Maintains Neutral on Sarepta Therapeutics, Raises Price Target to $16

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics with a Neutral and raises the price target from $15 to $16.

BusinessWire

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2025 financial results after the Nasdaq Global Market closes on Monday, Nov. 3, 2025.